Proliferative vitreoretinopathy: Current and emerging treatments

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1325-1333

  Sadaka, Ama ^a   Giuliari, Gian Paolo ^b,c  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b Centro de Cirugia Oftalmologica CECOF   (Venezuela)

^c Hospital Dr Domingo Luciani   (Venezuela)

Author keywords

Proliferative vitreoretinopathy; Retinal detachment; Vision loss

Indexed keywords

6,7 DIMETHYL 2 PHENYLQUINOXALINE; ACETYLCYSTEINE; AGENTS ACTING ON THE EYE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; COLCHICINE; CORTICOSTEROID; DAUNORUBICIN; DEXAMETHASONE; DEXAMETHASONE DIPHOSPHATE; ETOPOSIDE; FLUOROURACIL; GLUCOSAMINE; HERBIMYCIN; HYPERICIN; ISOTRETINOIN; METHYLPREDNISOLONE; MITOMYCIN C; PACLITAXEL; PLACEBO; RIBOZYME; SURAMIN; TACROLIMUS; TRANLISAT; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VIT 100;

CELL LOSS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; PROTEIN FUNCTION; RETINA DETACHMENT; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; STEROID THERAPY; STRATEGIC PLANNING; TREATMENT PLANNING; VITRECTOMY; VITREORETINOPATHY;

EID: 84865804817     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S27896     Document Type: Review

References (81)

1. [No authors listed]. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90(2):121-125.
2. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43(1):3-18.
3. Wilkins RB, Kulwin DR, Wendell L. Hughes Lecture. Wound healing. Ophthalmology. 1979;86(4):507-510.
4. Vinores SA, Campochiaro PA, Conway BP. Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Invest Ophthalmol Vis Sci. 1990;31(1):14-28.
5. Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol. 1992;36(5):373-384.
6. Heriot WJ, Machemer R. Pigment epithelial repair. Graefes Arch Clin Exp Ophthalmol. 1992;230(1):91-100.
7. Anderson DH, Stern WH, Fisher SK, Erickson PA, Borgula GA. The onset of pigment epithelial proliferation after retinal detachment. Invest Ophthalmol Vis Sci. 1981;21(1 Pt 1):10-16.
8. Mueller-Jensen K, Machemer R, Azarnia R. Autotransplantation of retinal pigment epithelium in intravitreal diffusion chamber. Am J Ophthalmol. 1975;80(3 Pt 2):530-537.
9. Campochiaro PA, Bryan JA 3rd, Conway BP, Jaccoma EH. Intravitreal chemotactic and mitogenic activity. Implication of blood-retinal barrier breakdown. Arch Ophthalmol. 1986;104(11):1685-1687.
10. Erickson PA, Fisher SK, Anderson DH, Stern WH, Borgula GA. Retinal detachment in the cat: the outer nuclear and outer plexiform layers. Invest Ophthalmol Vis Sci. 1983;24(7):927-942.
11. Cook B, Lewis GP, Fisher SK, Adler R. Apoptotic photoreceptor degeneration in experimental retinal detachment. Invest Ophthalmol Vis Sci. 1995;36(6):990-996.
12. Lei H, Rheaume MA, Kazlauskas A. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Res. 2010;90(3):376-381.
13. Heldin CH, Westermark B. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul. 1990;1(8): 555-566.
14. Cui J, Lei H, Samad A, et al. PDGF receptors are activated in human epiretinal membranes. Exp Eye Res. 2009;88(3):438-444.
15. Lei H, Hovland P, Velez G, et al. A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2007;48(5):2335-2342.
16. Yamada H, Yamada E, Ando A, et al. Platelet-derived growth factor-A-induced retinal gliosis protects against ischemic retinopathy. Am J Pathol. 2000;156(2):477-487.
17. Mori K, Gehlbach P, Ando A, et al. Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy. Invest Ophthalmol Vis Sci. 2002;43(6):2001-2006.
18. Ikuno Y, Leong FL, Kazlauskas A. Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor. Invest Ophthalmol Vis Sci. 2000;41(10): 3107-3116.
19. Campochiaro PA, Hackett SF, Vinores SA, et al. Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells. J Cell Sci. 1994;107(Pt 9):2459-2469.
20. Ikuno Y, Kazlauskas A. An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor. Invest Ophthalmol Vis Sci. 2002;43(7):2406-2411.
21. Zheng Y, Ikuno Y, Ohj M, et al. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn J Ophthalmol. 2003;47(2):158-165.
22. Lei H, Velez G, Hovland P, Hirose T, Gilbertson D, Kazlauskas A. Growth factors outside the PDGF family drive experimental PVR. Invest Ophthalmol Vis Sci. 2009;50(7):3394-3403.
23. Lei H, Kazlauskas A. Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J Biol Chem. 2009;284(10): 6329-6336.
24. Pennock S, Kazlauskas A. Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses. Mol Cell Biol. 2012;32(10):1955-1966.
25. Cassidy L, Barry P, Shaw C, Duffy J, Kennedy S. Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders. Br J Ophthalmol. 1998;82(2): 181-185.
26. Tanihara H, Yoshida M, Matsumoto M, Yoshimura N. Identification of transforming growth factor-beta expressed in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1993;34(2): 413-419.
27. Pfeffer BA, Flanders KC, Guerin CJ, Danielpour D, Anderson DH. Transforming growth factor beta 2 is the predominant isoform in the neural retina, retinal pigment epithelium-choroid and vitreous of the monkey eye. Exp Eye Res. 1994;59(3):323-333.
28. Yokoyama K, Kimoto K, Itoh Y, et al. The PI3K/Akt pathway mediates the expression of type I collagen induced by TGF-beta2in human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol. 2012; 250(1):15-23.
29. Kimoto K, Nakatsuka K, Matsuo N, Yoshioka H. p38 MAPK mediates the expression of type I collagen induced by TGF-beta 2in human retinal pigment epithelial cells ARPE-19. Invest Ophthalmol Vis Sci. 2004;45(7):2431-2437.
30. Carrington L, McLeod D, Boulton M. IL-10 and antibodies to TGF-beta2 and PDGF inhibit RPE-mediated retinal contraction. Invest Ophthalmol Vis Sci. 2000;41(5):1210-1216.
31. Connor TB Jr, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989;83(5):1661-1666.
32. Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci. 1999;40(3):705-712.
33. Nassar K, Luke J, Luke M, et al. The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR). Graefes Arch Clin Exp Ophthalmol. 2011;249(11):1649-1660.
34. Kita T. Molecular mechanisms of preretinal membrane contraction in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Nihon Ganka Gakkai Zasshi. 2010;114(11):927-934.
35. Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112(2):159-165.
36. Girard P, Mimoun G, Karpouzas I, Montefiore G. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina. 1994;14(5):417-424.
37. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21(1): 127-144.
38. Nagasaki H, Shinagawa K, Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res. 1998;17(1):77-98.
39. Ricker LJ, Kessels AG, de Jager W, Hendrikse F, Kijlstra A, la Heij EC. Prediction of proliferative vitreoretinopathy after retinal detachment surgery: potential of biomarker profiling. Am J Ophthalmol. Epub April 26, 2012.
40. Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol. 1998;116(1):69-77.
41. Borhani H, Peyman GA, Rahimy MH, Thompson H. Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU. Int Ophthalmol. 1995;19(1):43-49.
42. Moritera T, Ogura Y, Yoshimura N, et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1992;33(11):3125-3130.
43. Hui YN, Liang HC, Cai YS, Kirchhof B, Heimann K. Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefes Arch Clin Exp Ophthalmol. 1993;231(2):109-114.
44. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90(6):810-816.
45. Rubsamen PE, Cousins SW. Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy. Retina. 1997;17(1): 44-50.
46. Koerner F, Merz A, Gloor B, Wagner E. Postoperative retinal fibrosis-a controlled clinical study of systemic steroid therapy. Graefes Arch Clin Exp Ophthalmol. 1982;219(6):268-271.
47. Hui YN, Hu D. Prevention of experimental proliferative vitreo-retinopathy with daunomycin and triamcinolone based on the time course of the disease. Graefes Arch Clin Exp Ophthalmol. 1999; 237(7):601-605.
48. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000;84(9):1064-1067.
49. Bali E, Feron EJ, Peperkamp E, Veckeneer M, Mulder PG, van Meurs JC. The effect of a preoperative subconjuntival injection of dexamethasone on blood-retinal barrier breakdown following scleral buckling retinal detachment surgery: a prospective randomized placebo-controlled double blind clinical trial. Graefes Arch Clin Exp Ophthalmol. 2010;7:957-962.
50. Chen W, Chen H, Hou P, Fok A, Hu Y, Lam DS. Midterm results of low-dose intravitreal triamcinolone as adjunctive treatment for proliferative vitreoretinopathy. Retina. 2011;31(6):1137-1142.
51. Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108(7): 1179-1183.
52. Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007;114(4):698-704.
53. Sundaram V, Barsam A, Virgili G. Intravitreal low molecular weight heparin and 5-fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database Syst Rev. 2010;7:CD006421.
54. Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol. 1998;126(4):550-559.
55. Kumar A, Nainiwal S, Choudhary I, Tewari HK, Verma LK. Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery. Clin Experiment Ophthalmol. 2002;30(5): 348-351.
56. Lemor M, de Bustros S, Glaser BM. Low-dose colchicine inhibits astrocyte, fibroblast, and retinal pigment epithelial cell migration and proliferation. Arch Ophthalmol. 1986;104(8):1223-1225.
57. van Bockxmeer FM, Martin CE, Thompson DE, Constable IJ. Taxol for the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1985;26(8):1140-1147.
58. Daniels SA, Coonley KG, Yoshizumi MO. Taxol treatment of experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1990;228(6):513-516.
59. Berman DH, Gombos GM. Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? A controlled study in humans. Ophthalmic Surg. 1989;20(4):268-272.
60. Campochiaro PA, Hackett SF, Conway BP. Retinoic acid promotes density-dependent growth arrest in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1991;32(1):65-72.
61. Fekrat S, de Juan E Jr, Campochiaro PA. The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy. Ophthalmology. 1995;102(3): 412-418.
62. Chang YC, Hu DN, Wu WC. Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. Am J Ophthalmol. 2008;146(3):440-446.
63. Pan YT, Elbein AD. The formation of lipid-linked oligosaccharides in Madin-Darby canine kidney cells. Changes in oligosaccharide profiles induced by glucosamine. J Biol Chem. 1982;257(6):2795-2801.
64. Chesnokov V, Sun C, Itakura K. Glucosamine suppresses proliferation of human prostate carcinoma DU145cells through inhibition of STAT3 signaling. Cancer Cell Int. 2009;9:25.
65. Chang YH, Horng CT, Chen YH, et al. Inhibitory effects of glucosamine on endotoxin-induced uveitis in Lewis rats. Invest Ophthalmol Vis Sci. 2008;49(12):5441-5449.
66. Chen JT, Chen PL, Chang YH, Chien MW, Chen YH, Lu DW. Glucosamine sulfate inhibits leukocyte adhesion in response to cytokine stimulation of retinal pigment epithelial cells in vitro. Exp Eye Res. 2006;83(5):1052-1062.
67. Liang CM, Tai MC, Chang YH, et al. Glucosamine inhibits epidermal growth factor-induced proliferation and cell-cycle progression in retinal pigment epithelial cells. Mol Vis. 2010;16:2559-2571.
68. Liang CM, Tai MC, Chang YH, et al. Glucosamine inhibits epithelial-to-mesenchymal transition and migration of retinal pigment epithelium cells in culture and morphologic changes in a mouse model of proliferative vitreoretinopathy. Acta Ophthalmol. 2011;89(6): e505-e514.
69. Mandava N, Blackburn P, Paul DB, et al. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2002;43(10):3338-3348.
70. Schiff WM, Hwang JC, Ober MD, et al. Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch Ophthalmol. 2007; 125(9):1161-1167.
71. Kuo HK, Wu PC, Yang PM, Chen YH, Wu YC, Hu DN. Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy. J Ocul Pharmacol Ther. 2007; 23(1):14-200.
72. Turgut B, Uyar F, Ustundag B, Celiker U, Akpolat N, Demir T. The impact of tacrolimus on growth factors in experimental proliferative vitreoretinopathy. Retina. 2012;32(2):232-241.
73. Tahara YR, Sakamoto TR, Oshima YR, et al. The antidepressant hypericin inhibits progression of experimental proliferative vitreoretinopathy. Curr Eye Res. 1999;19(4):323-329.
74. Machado RA, Casella AM, Malaguido MR, Oguido AP. Experimental study of vitreoretinal proliferation inhibition by the use of hypericin. Arq Bras Oftalmol. 2009;72(5):650-654.
75. Imai K, Loewenstein A, Koroma B, Grebe R, de Juan E Jr. Herbimycin A in the treatment of experimental proliferative vitreoretinopathy: toxicity and efficacy study. Graefes Arch Clin Exp Ophthalmol. 2000;238(5): 440-447.
76. Eibl KH, Lewis GP, Betts K, et al. The effect of alkylphosphocholines on intraretinal proliferation initiated by experimental retinal detachment. Invest Ophthalmol Vis Sci. 2007;48(3):1305-1311.
77. Ito S, Sakamoto T, Tahara Y, et al. The effect of tranilast on experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1999;237(8):691-696.
78. Oshima Y, Sakamoto T, Hisatomi T, Tsutsumi C, Ueno H, Ishibashi T. Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy. Gene Ther. 2002;9(18):1214-1220.
79. de Souza OF, Sakamoto T, Kimura H, et al. Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin. Ophthalmologica. 1995;209(4):212-216.
80. Yu HG, Chung H. Antiproliferative effect of mitomycin C on experimental proliferative vitreoretinopathy in rabbits. Korean J Ophthalmol. 1997;11(2):98-105.
81. Lei H, Velez G, Cui J, et al. N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol. 2010;177(1):132-140.